{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:31:17Z","timestamp":1760149877277,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Background: Severe renal dysfunction (SRD), an advanced stage of chronic kidney disease (CKD), can limit the treatment options for acute stroke (AS) patients. Therefore, it is important to investigate the associated factors of SRD in AS patients to inhibit CKD progression to SRD before AS. Sex differences exist in the renal function. Therefore, we investigated the frequency of SRD and its associated factors among AS patients by sex. Methods: Our cross-sectional study included patients admitted within 24 h of AS onset between 2013 and 2019 with available pre-stroke medication information. We used the Cockcroft\u2013Gault equation for calculating the creatinine clearance (Ccr) and defined SRD as a Ccr &lt; 30 mL\/min. We performed multivariable logistic regression analysis to identify the independent factors associated with SRD. Results: Out of 4294 patients, 3472 matched our criteria. Of these, 1905 (54.9%) were male, with median ages of 75 and 81 years for males and females, respectively. The frequency of SRD was 9.7% in males and 18.7% in females. Loop diuretics and anemia were associated factors of SRD. Conclusions: Pre-stroke loop diuretics and anemia in elderly patients were associated factors of SRD in both sexes. Individualized drug therapy and anemia management are essential to prevent SRD.<\/jats:p>","DOI":"10.3390\/jcdd10090405","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T23:17:20Z","timestamp":1695165440000},"page":"405","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-Stroke Loop Diuretics and Anemia in Elderly Patients Are Associated Factors of Severe Renal Dysfunction at the Time of Acute Stroke Onset"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6108-7048","authenticated-orcid":false,"given":"Takahisa","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Stroke Treatment, Shonan Kamakura General Hospital, Kamakura City 247-8533, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsundo","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Stroke Treatment, Shonan Kamakura General Hospital, Kamakura City 247-8533, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Stroke Treatment, Shonan Kamakura General Hospital, Kamakura City 247-8533, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Stroke Treatment, Shonan Kamakura General Hospital, Kamakura City 247-8533, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/archinte.161.9.1207","article-title":"Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988\u20131994)","volume":"161","author":"Coresh","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/kisup.2013.79","article-title":"Risk factors for chronic kidney disease: An update","volume":"3","author":"Kazancioglu","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Nazzal, Z., Hamdan, Z., Masri, D., Abu-Kaf, O., and Hamad, M. (2020). Prevalence and risk factors of chronic kidney disease among Palestinian type 2 diabetic patients: A cross-sectional study. BMC Nephrol., 21.","DOI":"10.1186\/s12882-020-02138-4"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1161\/STROKEAHA.119.025442","article-title":"Does Chronic Kidney Disease Predict Stroke Risk Independent of Blood Pressure?: A systematic review and meta-regression","volume":"50","author":"Kelly","year":"2019","journal-title":"Stroke"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfm051","article-title":"Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population\u2014the Ohasama study","volume":"22","author":"Nakayama","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2169\/internalmedicine.47.0906","article-title":"Chronic kidney disease in Japan","volume":"47","author":"Iseki","year":"2008","journal-title":"Intern. Med."},{"key":"ref_8","first-page":"552","article-title":"Grupo de Investigacion ERCA. Prevalence of chronic kidney disease in patients with type 2 diabetes mellitus treated in primary care","volume":"30","year":"2010","journal-title":"Nefrologia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s10157-016-1309-1","article-title":"Risk factors for CKD progression in Japanese patients: Findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study","volume":"21","author":"Inaguma","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","article-title":"Management of hypertension in chronic kidney disease","volume":"79","author":"Pugh","year":"2019","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/ckj\/sfab016","article-title":"Prevalence, recognition and management of chronic kidney disease in Japan: Population-based estimate using a healthcare database with routine health checkup data","volume":"14","author":"Takeuchi","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"ref_13","unstructured":"(2023, August 06). Januivia Highlights of Prescribing Information, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=f85a48d0-0407-4c50-b0fa-7673a160bf01&type=display."},{"key":"ref_14","unstructured":"Report on the Deliberation Results (2023, August 06). RADICUT Injection 30 mg, Available online: https:\/\/www.pmda.go.jp\/files\/000212453.pdf."},{"key":"ref_15","first-page":"68","article-title":"Sulfonylurea induced severe hypoglycemia in a diabetic with renal failure\u2014A case report","volume":"3","author":"Zaid","year":"2015","journal-title":"J. Biosci. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11239-017-1483-3","article-title":"Oral antiplatelet drugs in patients with chronic kidney disease (CKD): A review","volume":"43","author":"Ibrahim","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in chronic kidney disease: From guidelines to clinical practice","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2215\/CJN.04330418","article-title":"Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD","volume":"14","author":"Sinha","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1161\/STROKEAHA.120.030272","article-title":"Systolic blood pressure reduction and acute kidney injury in intracerebral hemorrhage","volume":"51","author":"Qureshi","year":"2020","journal-title":"Stroke"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ponchia, P.I., Ahmed, R., Farag, M., and Alkhalil, M. (2022). Antiplatelet therapy in end-stage renal disease patients on maintenance dialysis: A state-of-the-art review. Cardiovasc. Drugs Ther.","DOI":"10.1007\/s10557-022-07366-4"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e012052","DOI":"10.1161\/JAHA.119.012052","article-title":"Renal dysfunction and in-hospital outcomes in patients with acute ischemic stroke after intravenous thrombolytic therapy","volume":"8","author":"Rao","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa1415061","article-title":"Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke","volume":"372","author":"Saver","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1706442","article-title":"Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct","volume":"378","author":"Nogueira","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.21037\/atm.2020.03.62","article-title":"Understanding sex differences in progression and prognosis of chronic kidney disease","volume":"8","author":"Kattah","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/endocrines2030019","article-title":"Sex differences in renal function: Participation of gonadal hormones and prolactin","volume":"2","author":"Echavarria","year":"2021","journal-title":"Endocrines"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: A KDIGO controversies conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/ndt\/gfg1084","article-title":"The cardio-renal anaemia syndrome: Does it exist?","volume":"18","author":"Silverberg","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/STROKEAHA.116.016022","article-title":"Risk of stroke in patients with heart failure: A population-based 30-year cohort study","volume":"48","author":"Adelborg","year":"2017","journal-title":"Stroke"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1523-1755.2004.00863.x","article-title":"Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy","volume":"66","author":"Mohanram","year":"2004","journal-title":"Kidney Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfg021","article-title":"Haematocrit and the risk of developing end-stage renal disease","volume":"18","author":"Iseki","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1523-1755.2004.00797.x","article-title":"Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial","volume":"66","author":"Gouva","year":"2004","journal-title":"Kidney Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2009.09.019","article-title":"Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review","volume":"55","author":"Gandra","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1744-9987.2012.01082.x","article-title":"High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients","volume":"16","author":"Tsubakihara","year":"2012","journal-title":"Ther. Apher. Dial."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Locatelli","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Iseki, K., and Yamagata, K. (2016). A practical approach of salt and protein restriction for CKD patients in Japan. BMC Nephrol., 17.","DOI":"10.1186\/s12882-016-0298-3"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1253\/circj.CJ-20-1215","article-title":"Sodium Restriction Counseling Reduces Cardiac Events in Patients with Heart Failure","volume":"85","author":"Nakajima","year":"2021","journal-title":"Circ. J."},{"key":"ref_40","first-page":"1000164","article-title":"Relationship of loop diuretic dosing and acute changes in renal function during hospitalization for heart failure","volume":"2","author":"Krivospitskaya","year":"2011","journal-title":"J. Clin. Exp. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"(2000). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA, 288, 2981\u20132997.","DOI":"10.1001\/jama.288.23.2981"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"(2000). Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT collaborative research group. JAMA, 283, 1967\u20131975.","DOI":"10.1001\/jama.283.15.1967"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"F548","DOI":"10.1152\/ajprenal.00233.2021","article-title":"Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling","volume":"321","author":"Moore","year":"2021","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhao, M., Zhang, Z., Pan, Z., Ma, S., Chang, M., Fan, J., Xue, S., Wang, Y., Qu, H., and Zhang, Y. (2023). N-\/T-Type vs. L-Type calcium channel blocker in treating chronic kidney disease: A systematic review and meta-analysis. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030338"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5694\/j.1326-5377.2000.tb125548.x","article-title":"Diuretics, ACE inhibitors and NSAIDs\u2013The triple whammy","volume":"172","author":"Thomas","year":"2000","journal-title":"Med. J. Aust."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ki.2015.101","article-title":"Combined use of nonsteroidal anti-inflammatory drugs with diuretics and\/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury","volume":"88","author":"Dreischulte","year":"2015","journal-title":"Kidney Int."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wozniak, E., Broncel, M., Bukowska, B., and Gorzelak-Pabis, P. (2020). The Protective Effect of Dabigatran and Rivaroxaban on DNA oxidative changes in a model of vascular endothelial damage with oxidized cholesterol. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21061953"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Rogula, S., Gasecka, A., Mazurek, T., Navarese, E.P., Szarpak, L., and Filipiak, K.J. (2022). Safety and Efficacy of DOACs in patients with advanced and end-stage renal disease. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19031436"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"The","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/9\/405\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:54:03Z","timestamp":1760129643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/9\/405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcdd10090405"],"URL":"https:\/\/doi.org\/10.3390\/jcdd10090405","relation":{},"ISSN":["2308-3425"],"issn-type":[{"type":"electronic","value":"2308-3425"}],"subject":[],"published":{"date-parts":[[2023,9,19]]}}}